Upon completion of this
activity, participants should be able to: - Discuss
the emerging medicare data that supports the correlation between anemia and morbidity, mortality, and hospitalization
- Describe new
data that further links anemia and cardiovascular disease
- Discuss the advantages current therapies have on clinical
practices
- Describe
the clinical and economic impact of anemia management in various pratice settings
|
Allan Collins,
M.D.
Nephrology Analyst Services
Minneapolis, Minnesota
Mahesh Kirshnan, M.D.
Virginia Nephrology Group
Arlington, Virginia
Brian Pereira, M.D.
New England Healthcare Foundation
Boston, Massachusetts
Robert Toto, M.D.
University of Texas Southwestern Medical Center
Dallas, Texas
| |
 |
| This satellite symposium is sponsored by an unrestricted educational grant
from Amgen, Inc. This activity has been planned and produced in accordance with CME guidelines and policies. From a CME symposium held on November, 2002 at the The 35th Annual Meeting of the American
Society of Nephrology in Philadelphia, PA. This symposium was approved by ASN. It was not part of the official ASN Annual Meeting.
The
Postgraduate Institute for Medicine designates this activity for a maximum
of 2 hours in category 1 credit toward the AMA Physician's Recognition Award. |
| | Estimated
time to complete activity: 2.0 hours
Posting date: January 2003
Review date: January, 2003
Expiration date: January,
2004 | 
To
obtain a statement of participation, you must complete the post-test by recording
the best answer to each question in the answer key on the evaluation form, complete
the evaluation form, and mail or fax the evaluation form with answer key to the
Postgraduate Institute for Medicine.
|  |
Post-test
and evaluation form is at this
link, but you must listen to all
talks from this symposium prior to completing
the test
|
This activity
as been desighned to meet the educational needs of nephrologists involved in the
treatment of patients with CKD and anemia.
Chronic
kidney disease affects 30-40 million Americans and is hence a major health care
problem. Anemia of CKD is a preventable and treatable complication of CKD and
is yet under recognized and under treated. Nephrologists should be sensitized
to the above two facts and are the target audience for this message. This emerging
information would be necessary to improve anemia management and consequently classical
outcomes.
|
ACCREDITATION STATEMENT : |
This activity has been planned and implemented in accordance with the Essential
Areas and Policies of the Accreditation Council for Continuing Medical Education
(ACCME) through the joint sponsorship of the Postgraduate Institute for Medicine
and HealthVizion Communications. The Postgraduate Institute for Medicine is accredited
by the ACCME to provide continuing medical education for physicians.
|
DESIGNATION STATEMENT(S) : | The
Postgraduate Institute for Medicine designates this educational activity for a
maximum of 2 hours in category 1 credit toward the AMA Physician's Recognition
Award. Each physician should claim only those hours of credit that he/she actually
spent in the activity.
|
FACULTY DISCLOSURE STATEMENTS : | Postgraduate
Institute for Medicine has a conflict of interest policy that requires course
faculty to disclose any real or apparent commercial financial affiliations related
to the content of their presentations/materials. It is not assumed that these
financial interests or affiliations will have an adverse impact on faculty presentations;
they are simply noted here to fully inform participants.
Dr. Collins: Grants/Research Support: Amgen, Inc.
Dr. Krishman: Is a consultant and clinical investigator for AMGEN, Inc.
Dr. Pereira: Grants/Research Support: Amgen, Inc. Consultant: Amgen, Inc., Baxter. Speakers' Bureau: Amgen, Inc.
Dr. Toto: Grants/Research Support: Amgen
|
DISCLOSURE OF UNLABELED USE : | Faculty
of this CME activity may include discussions of products or devices that are not
currently labeled for use by the FDA. Faculty members will disclose to the audience
any reference to an unlabeled or investigational use. The Postgraduate Institute
for Medicine, HealthVizion Communications, and Amgen, Inc. do not recommend the
use of any agent outside of the labeled indications. Please refer to the official
prescribing information for each product for discussion of approved indications,
contraindications and warnings.
Participants
have an implied responsibility to use the newly acquired information to enhance
patient outcomes and their own professional development. The information presented
in this activity is not meant to serve as a guideline for patient management.
Any procedures, medications, or other courses of diagnosis or treatment discussed
or suggested in this activity should not be used by clinicians without evaluation
of their patient's conditions and possible contraindications on dangers in use,
review of any applicable manufacturer's product information, and comparison with
recommendations of other authorities. |
|
